Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cellectar Biosciences Inc (CLRB)

Cellectar Biosciences Inc (CLRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,646
  • Shares Outstanding, K 4,240
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,580 K
  • EBIT $ -30 M
  • EBITDA $ -30 M
  • 60-Month Beta 0.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.55

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 91.14%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 890.15% on 01/13/25
  • IV Low 0.00% on 12/02/25
  • Expected Move (DTE 77) 0.04 (1.16%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 0
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 4
  • Open Int (30-Day) 328
  • Expected Range 3.63 to 3.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.20
  • Number of Estimates 2
  • High Estimate -1.19
  • Low Estimate -1.21
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.71 +40.22%
on 11/17/25
3.83 -0.78%
on 12/04/25
+0.45 (+13.43%)
since 11/04/25
3-Month
2.71 +40.22%
on 11/17/25
6.52 -41.72%
on 10/06/25
-1.18 (-23.69%)
since 09/04/25
52-Week
2.71 +40.22%
on 11/17/25
44.70 -91.50%
on 12/05/24
-40.30 (-91.38%)
since 12/04/24

Most Recent Stories

More News
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s Macroglobulinemia in 2026 Following Advice and Guidance from Scientific...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.80 (+2.98%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025

FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.80 (+2.98%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

FLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.80 (+2.98%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.80 (+2.98%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Raises $5.8M Through Warrant Exercise

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cellectar...

CLRB : 3.80 (+2.98%)
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.80 (+2.98%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Receives EMA Advice on Drug Filing

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cellectar...

CLRB : 3.80 (+2.98%)
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)

Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM  Expected...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.80 (+2.98%)
CLRBW : 0.13 (+348.28%)
Oppenheimer Remains a Hold on Cellectar Biosciences (CLRB)

Oppenheimer analyst maintained a Hold rating on Cellectar Biosciences today. The company’s shares closed yesterday at $5.77.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55%...

CLRB : 3.80 (+2.98%)
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

FLORHAM PARK, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.80 (+2.98%)
CLRBW : 0.13 (+348.28%)

Business Summary

Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in...

See More

Key Turning Points

3rd Resistance Point 4.10
2nd Resistance Point 3.97
1st Resistance Point 3.88
Last Price 3.80
1st Support Level 3.66
2nd Support Level 3.53
3rd Support Level 3.44

See More

52-Week High 44.70
Fibonacci 61.8% 28.66
Fibonacci 50% 23.70
Fibonacci 38.2% 18.75
Last Price 3.80
52-Week Low 2.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar